Featured Press Releases

Agomab Receives FDA Orphan Drug Designation for AGMB-447 in Idiopathic Pulmonary Fibrosis

Agomab Receives FDA Orphan Drug Designation for AGMB-447 in Idiopathic Pulmonary Fibrosis

Genesis Medtech secures Chinese approval for its groundbreaking 90° articulation powered surgical stapler, setting new standards in precision surgery

Genesis Medtech secures Chinese approval for its groundbreaking 90° articulation powered surgical stapler, setting new standards in precision surgery

  • 02 Jan 2025

Genesis Medtech is proud to announce that iReach Omnia, the world's first powered stapler with 90°...

Cytonics Begins First-In-Human Phase 1 Clinical Study for CYT-108 in Osteoarthritis Knee Patients

Cytonics Begins First-In-Human Phase 1 Clinical Study for CYT-108 in Osteoarthritis Knee Patients

Brazilian Entrepreneur Launches Entourage Phytolab on One Lavi

Brazilian Entrepreneur Launches Entourage Phytolab on One Lavi

Promega introduces the GloMax® Galaxy Bioluminescence Imager to illuminate protein dynamics in real time

Promega introduces the GloMax® Galaxy Bioluminescence Imager to illuminate protein dynamics in real time

2025 Interim Results and Business Updates Announced by Innovent

2025 Interim Results and Business Updates Announced by Innovent

Niagen Bioscience

Niagen Bioscience's Pharmaceutical-Grade Niagen™ IV and Injections Are Now Available at Over 50 iCRYO Clinics and More Than 900 Clinics Nationwide

  • Niagen Bioscience, Inc
  • 01 Oct 2025
Novartis Receives FDA Approval for Rhapsido® (remibrutinib), the First Oral, Targeted BTKi Treatment for Chronic Spontaneous Urticaria (CSU

Novartis Receives FDA Approval for Rhapsido® (remibrutinib), the First Oral, Targeted BTKi Treatment for Chronic Spontaneous Urticaria (CSU

  • Novartis Pharmaceuticals Corporation
  • 01 Oct 2025
CollPlant Biotechnologies Announces Positive Non-Clinical Study Results for Its Photocurable Regenerative Dermal and Soft Tissue Filler

CollPlant Biotechnologies Announces Positive Non-Clinical Study Results for Its Photocurable Regenerative Dermal and Soft Tissue Filler

  • CollPlant
  • 30 Sep 2025
Corstasis Therapeutics and U.S. Heart and Vascular® will collaborate to improve heart failure care with ENBUMYST™ (Bumetanide Nasal Spray

Corstasis Therapeutics and U.S. Heart and Vascular® will collaborate to improve heart failure care with ENBUMYST™ (Bumetanide Nasal Spray

  • Corstasis Therapeutics Inc.
  • 29 Sep 2025
Leqembi® has received approval for intravenous maintenance treatment in China

Leqembi® has received approval for intravenous maintenance treatment in China

  • BioArctic AB
  • 29 Sep 2025
At the Heart Failure Society of America, Bayer will showcase new data for KERENDIA® (finerenone)

At the Heart Failure Society of America, Bayer will showcase new data for KERENDIA® (finerenone)

  • Bayer
  • 25 Sep 2025

Most Popular
October   2025
M T W T F S S
    1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31    

User Area

Discover

Engage with Us

© 2024 Pharmaceutical Era — A product of HISSM. All Rights Reserved.